Intersect ENT (NASDAQ:XENT) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Tuesday.
XENT has been the subject of several other reports. Guggenheim reiterated a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. Zacks Investment Research restated a “hold” rating on shares of Intersect ENT in a report on Saturday, April 7th. JPMorgan Chase upgraded Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Finally, ValuEngine upgraded Intersect ENT from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Intersect ENT presently has an average rating of “Buy” and an average target price of $33.38.
Shares of Intersect ENT stock opened at $40.80 on Tuesday. The stock has a market cap of $1,178.79, a PE ratio of -72.86 and a beta of 0.75. Intersect ENT has a 52-week low of $16.00 and a 52-week high of $40.80.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $37.66, for a total value of $483,290.78. Following the transaction, the chief financial officer now directly owns 36,265 shares of the company’s stock, valued at approximately $1,365,739.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Richard E. Kaufman sold 50,000 shares of Intersect ENT stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $33.33, for a total value of $1,666,500.00. Following the completion of the transaction, the chief operating officer now directly owns 107,470 shares in the company, valued at $3,581,975.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 130,623 shares of company stock valued at $4,600,347. Corporate insiders own 13.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in Intersect ENT in the 4th quarter worth approximately $370,000. Wolverine Trading LLC bought a new position in Intersect ENT in the 4th quarter worth approximately $341,000. Elkfork Partners LLC bought a new position in Intersect ENT in the 4th quarter worth approximately $237,000. TIAA CREF Investment Management LLC increased its position in Intersect ENT by 7.7% in the 4th quarter. TIAA CREF Investment Management LLC now owns 137,428 shares of the medical equipment provider’s stock worth $4,453,000 after buying an additional 9,792 shares during the period. Finally, Teachers Advisors LLC increased its position in Intersect ENT by 333.9% in the 4th quarter. Teachers Advisors LLC now owns 288,732 shares of the medical equipment provider’s stock worth $9,355,000 after buying an additional 222,195 shares during the period. 84.49% of the stock is currently owned by institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.